GLPwatch
Papers (9189)
Page 113 of 154, ranked by citation count.
- Indirect comparison of lixisenatide versus neutral protamine Hagedorn insulin as add-on to metformin and sulphonylurea in patients with type 2 diabetes mellitus.
- Current and Emerging Parenteral and Peroral Medications for Weight Loss: A Narrative Review.
- Incretin receptor agonism during pregnancy: implications for mother and baby.
- Glycaemic variability in patients with type 2 diabetes mellitus treated with dulaglutide, with and without concomitant insulin: Post hoc analyses of randomized clinical trials.
- An Evaluation of the Clinical Therapeutic Effect of Lixisenatide in Type 2 Diabetes Patients: A Systematic Literature Review.
- New hypoglycemic agents and the kidney: what do the major trials tell us?
- Glucagon-Like Peptide-1 Receptor Agonist Therapy Does Not Increase Gastrointestinal Adverse Events in Patients with Inflammatory Bowel Disease.
- Glucagon-like peptide-1 receptor agonists and the cardiorenal axis in Type 2 diabetes: a focus on dulaglutide.
- Expression of NUCB2/nesfatin-1 in the taste buds of rats.
- The novel GLP-1 / GIP dual agonist DA3-CH is more effective than liraglutide in the MPTP mouse model of Parkinson's disease.
- Cost-effectiveness analysis of once-weekly semaglutide vs. once-daily liraglutide administered subcutaneously in patients with overweight and obesity: a decision analysis.
- An open-label 16-week study of liraglutide in adolescents with obesity post-sleeve gastrectomy.
- Off-label GLP-1 weight-loss medicine use among online bodybuilders: Folk pharmacology, risk and harm reduction.
- Incretin Mimetics Restore the ER-Mitochondrial Axis and Switch Cell Fate Towards Survival in LUHMES Dopaminergic-Like Neurons: Implications for Novel Therapeutic Strategies in Parkinson's Disease.
- GLP-1RA versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: An updated meta-analysis of randomized controlled trials.
- Feasibility of once weekly exenatide-LAR and enhanced diabetes care in Indigenous Australians with type 2 diabetes (Long-acting-Once-Weekly-Exenatide laR-SUGAR, 'Lower SUGAR' study).
- 68Ga-Exendin-4 PET/CT Differentiates Insulinoma From Accessory Spleen in a Patient Presenting Indeterminate MRI and 68Ga-DOTATATE PET/CT Findings.
- Effect of Oral Semaglutide on Volumetric BMD and Bone Microarchitecture in Overweight/Obese Individuals with Type 2 Diabetes.
- Diabetic kidney disease in 2017: A new era in therapeutics for diabetic kidney disease.
- Efficacy and safety of European Medicines Agency (EMA)-approved pharmacological, endoscopic, and surgical treatments in different classes of obesity: A network meta-analysis of randomised controlled trials for the development of the SIO (Società Italiana Obesità) Italian guidelines for the diagnosis and treatment of overweight and obesity.
- Metabolic effects of combined glucagon receptor antagonism and glucagon-like peptide-1 receptor agonism in high fat fed mice.
- Evaluation of Drug Efficacy of GLP-1 Receptor Agonists and DPP-4 Inhibitors Based on Target Molecular Binding Occupancy.
- Scientific report: a case of acute pancreatitis due to liraglutide.
- Cardiovascular benefits of semaglutide: a systematic review and meta-analysis of randomized controlled trials.
- Revolutionizing diabetes care: unveiling tirzepatide's potential in glycemic control and beyond.
- GLP-1/GIP dual agonist tirzepatide alleviates mice model of Parkinson's disease by promoting mitochondrial homeostasis.
- Dosing Patterns of Dulaglutide and Semaglutide in Patients with Type 2 Diabetes in the United Kingdom and Germany: A Retrospective Cohort Study.
- Effects of Liraglutide on Leptin Promoter Methylation in Ovarian Granulosa Cells of Obese Polycystic Ovary Syndrome Patients.
- Protective effects of liraglutide on hypercholesterolemia-associated atherosclerosis involve attenuation of endothelial-monocyte adhesion through down-regulating the LOX-1/NF-κB signaling pathway.
- Comparing the effects of twice-daily exenatide and insulin on renal function in patients with type 2 diabetes mellitus: secondary analysis of a randomized controlled trial.
- Screening for Inflammatory Markers Identifies IL-18Rα as a Potential Link between Exenatide and Its Anti-Inflammatory Effect: New Results from the Combat-JUDO Randomized Controlled Trial.
- Semaglutide Aggregates into Oligomeric Micelles and Short Fibrils in Aqueous Solution.
- Aptamer Functionalized Liposomes Co-Loaded with Exenatide-4 and Coenzyme Q10 Ameliorate Type 2 Diabetes Mellitus by Improving Pancreatic β Cell Function.
- Linoleic acid co-administration promotes oral delivery of exenatide-loaded butyrate-decorated nanocapsules.
- Cyclic Hydroxylamines for Native Residue-Forming Peptide Ligations: Synthesis of Ubiquitin and Tirzepatide.
- Noninvasive Evaluation of GIP Effects on β-Cell Mass Under High-Fat Diet.
- Impact of Semaglutide Administration on Weight Loss After Bariatric Surgery: A Meta-Analysis.
- Addition of once daily prandial lixisenatide to basal insulin therapy in patients with type-2 diabetes results in a reduction of HbA1c as an effect of postprandial glucose lowering.
- Allodynia (skin tenderness) associated with semaglutide: A case series.
- The evolving world of GLP-1 agonist therapies for type 2 diabetes.
- Cost-utility analysis and drug pricing for tirzepatide for type 2 diabetes in the Chinese market compared with semaglutide.
- A novel Dual GLP-1/CCK Receptor Agonist Improves Cognitive Performance and Synaptogenesis in the 5 × FAD Alzheimer Mouse Model.
- Combination therapy with Exendin-4 and islet transplantation as a synergistic treatment for diabetic nephropathy in rats.
- Comparative Analysis of Pioglitazone and Tirzepatide on Body Weight, Glucose Levels, Neuroinflammation, and Oxidative Stress in Diabetic Rats.
- Pulmonary artery pressure trajectories in heart failure patients treated with GLP-1 receptor agonists.
- New onset diabetic retinopathy with glucagon-like peptide-1 receptor agonists: A case report.
- Tirzepatide Associated With Improved Health-Related Quality of Life in Adults With Obesity or Overweight in SURMOUNT-4.
- Tirzepatide: NICE recommends another GLP-1 agonist for type 2 diabetes.
- Semaglutide, Ertugliflozin, and Deflazacort.
- SURMOUNT-2: new advances for treating obese type 2 diabetes with tirzepatide.
- Immunity against a therapeutic xenoprotein/Fc construct delivered by gene transfer is reduced through binding to the inhibitory receptor FcγRIIb.
- Lanifibranor and semaglutide demonstrate multiple metabolic benefits in free-choice diet induced obese hamster models of MASH and MetALD.
- Proinflammatory cytokine-induced alpha cell impairment in human islet microtissues is partially restored by dual incretin receptor agonism.
- Liraglutide's Effect on Weight Management in Subjects With Pre-diabetes: A Systematic Review & Meta-Analysis.
- Letter to the Editor: Comment on "The Impact of Chronic Liraglutide Therapy on Glucagon Secretion in Type 2 Diabetes: Insight From the LIBRA Trial" by Kramer C.K., et al.
- Use of glucagon-like peptide-1 receptor agonists in idiopathic intracranial hypertension : a systematic review.
- Investigating the potential non-authorized use of two different formulations of liraglutide in Europe: A real-world drug utilization study.
- Real-World Use of Once-Weekly Semaglutide in Thai Patients With Type 2 Diabetes Mellitus in a Private Hospital Setting.
- Once-daily liraglutide (1.2 mg) compared with twice-daily exenatide (10 μg) in the treatment of type 2 diabetes patients: An indirect treatment comparison meta-analysis.
- Fixed-ratio Combinations (basal Insulin Plus GLP-1RA) In Type 2 Diabetes. an Analytical Review Of Pivotal Clinical Trials.